47 results on '"Ezhil V"'
Search Results
2. Camera Ready Summary A Study and Analysis of Campus Recruitment Parameters and Selection Process
- Author
-
Kumar, Ezhil V, primary and Keerthy, Shanthi Vijaya, additional
- Published
- 2023
- Full Text
- View/download PDF
3. PO-1845 Investigating the use of Microsoft KinectV2 to monitor a patient’s breathing during Lung SBRT
- Author
-
Anastasi, G., primary, Evans, P., additional, Adams, E., additional, Clark, C., additional, Wells, K., additional, Nisbet, A., additional, and Ezhil, V., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Corneal microstructural changes of precise CHST6 gene mutation: a case series
- Author
-
Durga Murugan, Senthil Kumar Babu, Ezhil Vendhan Kalaimamani, and Kamaraj Raju
- Subjects
Macular corneal dystrophy (MCD) ,Carbohydrate sulfotransferase 6 gene (CHST6) ,Open Reading Frame mutation (ORF) ,In vivo confocal microscope (IVCM) ,Immunohistochemistry (IHC) ,Medicine (General) ,R5-920 ,Genetics ,QH426-470 - Abstract
Abstract Background Macular corneal dystrophy (MCD) is an inherited, autosomal recessive disorder of defective keratan sulfate (KS) metabolism. It is caused by the mutations in carbohydrate sulfotransferase 6 gene (CHST6) which is essential for the sulfation of KS. Unlike the western world, MCD is the most common corneal stromal dystrophy in India, especially in south Indian population; it could be due to high frequency of consanguineous marriages. Case presentation This study presents the clinical findings of one North Indian MCD family, including 6 patients and 3 unaffected relatives. We used slit lamp examination and in vivo confocal microscopy for assessment. Mutation screening was performed with Sanger sequencing, and corneal structure was analyzed through histochemistry and immunohistochemistry. Our comparative findings revealed that all the patients identified with the deletion of major portion of CHST6 that included the Open Reading Frame (ORF). Although all the patients showed significantly reduced central corneal thickness (CCT-250 μm), a drastic decrease in stromal keratocyte count, and depletion of Bowman’s layer compared to controls. Conclusions This study first time revealed that MCD patients from one family with a deletion of major portion of CHST6 that included ORF leads to severe corneal morphological changes.
- Published
- 2024
- Full Text
- View/download PDF
5. Study on the factors involved in the development of coronary collaterals in hypertensive and non-hypertensive patients of coronary artery disease
- Author
-
Senthil Kumar B, Kouser Banu Khaleeluddin, Sheeja Balakrishnan, G Yavabalakumaran, and Ezhil Vendhan K
- Subjects
coronary artery disease ,collateral formation ,cystatin –c ,coronary angiogram ,vegf ,Pharmacy and materia medica ,RS1-441 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Background: Coronary artery disease (CAD) results from the narrowing of coronary arteries that leads to inadequate blood supply to the heart muscles, resulting in Acute Coronary Syndrome (ACS). The coronary collaterals which develop will be an alternative source of blood flow in CAD. Myocardial ischemia stimulates the development of coronary collaterals by releasing various angiogenic growth factors, like the Vascular Endothelial Growth Factor (VEGF). Serum VEGF will serve as an important biomarker in CAD; thus, it can predict coronary collateral development. Aim: To study the factors affecting the development of coronary collaterals in hypertensive and non-hypertensive patients with CAD. Methods: The study includes 100 patients who have done coronary angiography, with an average age of 60±15. Consent was obtained from all patients, and 2 ml of blood was collected. The serum VEGF concentration and cystatin-C were quantified. Coronary Angiograms, along with other reports, were collected and analyzed. CAD was diagnosed for those with ≥ 70% stenosis inany one of the major coronary artery. Coronary collateral gradings was performed as per Rentrop Scoring system. The serum VEGF and cystatin-C levels were correlated with the collateral scores and other cardiovascular risk factors. Results: A significant correlation was found between the collateral scores and serum VEGF level in hypertensive patients only. No significant correlation was found between VEGF level, collateral scores and cardiovascular risk factors. Conclusions: Cardiovascular risk factors in turn increase the serum VEGF level, which results in collateral development. Age and sex did not show show any significant association especially old age and females, with serum VEGF levels.
- Published
- 2024
- Full Text
- View/download PDF
6. Prevalence and awareness of text neck syndrome and text thumb syndrome in young adult population
- Author
-
Senthil Kumar B, Kouser Banu Khaleeluddin, Saikarthick Jayakumar, and Ezhil Vendhan K
- Subjects
text neck syndrome ,thumb text syndrome ,mobile phone ,posture ,Pharmacy and materia medica ,RS1-441 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Background: The term "text neck" can be defined as repetitive strain injury and pain due to excessive viewing and texting on a smartphone for a prolonged duration. Long-term untreated text neck results in inflammation of ligaments and muscles, which can lead to permanent arthritic changes. Many smart phone users experience thumb/wrist pain, but some people who develop pain are smart phone addicts. The present study checks the prevalence and awareness of text neck and thumb text syndrome in young adults. Methods: A cross-sectional study was conducted with 200 volunteers between 18-25 years age who have been using mobile phone in the last 5 years. A structured questionnaire was created, validated, and used for the study. Descriptive statistics was used to assess responses received from participants. The prevalence of text neck syndrome and thumb text syndrome has been established. Results: About 50.3% of the participants were unaware of text neck syndrome and 57.1% of text thumb syndrome. Maximum mobile phone usage included texting and calls. About 45.2% of the participants use their right thumb and index finger to text. 33% of people have a head forward posture when using mobile phones. An analysis of pain, discomfort, and duration during mobile phone use was done and will be presented at a forum. Conclusion: The prevalence of text neck and thumb text syndrome in the young adult population indicates the need to plan future pain management strategies and increase user awareness
- Published
- 2024
- Full Text
- View/download PDF
7. P30.03 A Simple Solution to Screening for Dietetic Need in Patients with Advanced Non-Small Cell Lung Cancer
- Author
-
Phillips, I., primary, Hug, A., additional, Westran, N., additional, Allan, L., additional, Heinemann, C., additional, and Ezhil, V., additional
- Published
- 2021
- Full Text
- View/download PDF
8. PO-1554: Radiogenomics: A ‘Virtual Biopsy’ in Nonsmall Cell Lung Cancer?
- Author
-
Saxby, H., primary, Wang, H., additional, Ezhil, V., additional, Evans, P., additional, Halling-Brown, M., additional, Phillips, I., additional, Prakash, V., additional, and Nisbet, A., additional
- Published
- 2020
- Full Text
- View/download PDF
9. Symptom burden strongly correlates with the need for a dietitian in advanced NSCLC
- Author
-
Phillips, I., primary, Allan, L., additional, Hug, A., additional, Westran, N., additional, Heinemann, C., additional, Hewish, M., additional, Mehta, A., additional, Saxby, H., additional, Mainsiouw, L., additional, Boateng, S., additional, Evans, P., additional, and Ezhil, V., additional
- Published
- 2020
- Full Text
- View/download PDF
10. Stereotactic Ablative Body Radiotherapy to Treat Colorectal Oligometastases
- Author
-
Saxby, H., primary, Chandy, E., additional, Phillips, I., additional, and Ezhil, V., additional
- Published
- 2019
- Full Text
- View/download PDF
11. The stability of imaging biomarkers in radiomics: a framework for evaluation
- Author
-
Wang, H Y C, primary, Donovan, E M, additional, Nisbet, A, additional, South, C P, additional, Alobaidli, S, additional, Ezhil, V, additional, Phillips, I, additional, Prakash, V, additional, Ferreira, M, additional, Webster, P, additional, and Evans, P M, additional
- Published
- 2019
- Full Text
- View/download PDF
12. EP-1953 Lung tumour dynamics during SABR: Analysis of 415 CBCTs using a semi-automated contouring technique
- Author
-
Chandy, E., primary, Conway, L., additional, Distefano, G., additional, Earley, J., additional, Lamont, K., additional, Long, M., additional, Phillips, I., additional, Saxby, H., additional, South, C., additional, West, C., additional, and Ezhil, V., additional
- Published
- 2019
- Full Text
- View/download PDF
13. PO-1019 The elephant plot: Differentiating between early recurrence and Benign Lung Injury after SABR
- Author
-
Phillips, I., primary, Wang, H., additional, Evans, P., additional, Ezhil, V., additional, Saxby, H., additional, South, C., additional, Hussein, M., additional, Nisbet, A., additional, Alobaidli, S., additional, and Chandy, E., additional
- Published
- 2019
- Full Text
- View/download PDF
14. Acute radiation induced CT changes after stereotactic ablative body radiotherapy for primary non-small cell lung cancer
- Author
-
Saxby, H., primary, Chandy, E., additional, Phillips, I., additional, Prakash, V., additional, and Ezhil, V., additional
- Published
- 2019
- Full Text
- View/download PDF
15. The utility of cfDNA as a diagnostic tool in the management of EGFR-mutated non-small cell lung cancer (NSCLC): our regional off-study experience
- Author
-
Nageshwaran, S., primary, Ping, B., additional, Mehta, A., additional, Ezhil, V., additional, Feng, G., additional, Hall, J., additional, Shaheed, M., additional, Amin, N., additional, Faulkes, C., additional, Collins, N., additional, Illsley, M., additional, Matthew, H., additional, Bagwan, I., additional, Lee, K., additional, and Hewish, M., additional
- Published
- 2019
- Full Text
- View/download PDF
16. Outcomes after stereotactic ablative body radiotherapy for stage 1 lung cancer
- Author
-
Phillips, I., primary, Chandy, E., additional, Yusof, H., additional, Lodge, D., additional, Bishop, L., additional, Mahendran, P., additional, Halling-Brown, M., additional, Saxby, H., additional, and Ezhil, V., additional
- Published
- 2019
- Full Text
- View/download PDF
17. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
- Author
-
Abbosh, C, Birkbak, NJ, Wilson, GA, Jamal-Hanjani, M, Constantin, T, Salari, R, Quesne, JL, Moore, DA, Veeriah, S, Rosenthal, R, Marafioti, T, Kirkizlar, E, Watkins, TBK, McGranahan, N, Ward, S, Martinson, L, Riley, J, Fraioli, F, Bakir, MA, GrÖnroos, E, Zambrana, F, Endozo, R, Bi, WL, Fennessy, FM, Sponer, N, Johnson, D, Laycock, J, Shafi, S, Czyzewska-Khan, J, Rowan, A, Chambers, T, Matthews, N, Turajlic, S, Hiley, C, Lee, SM, Forster, MD, Ahmad, T, Falzon, M, Borg, E, Lawrence, D, Hayward, M, Kolvekar, S, Panagiotopoulos, N, Janes, SM, Thakrar, R, Ahmed, A, Blackhall, F, Summers, Y, Hafez, D, Naik, A, Ganguly, A, Kareht, S, Shah, R, Joseph, L, Quinn, AM, Crosbie, P, Naidu, B, Middleton, G, Langman, G, Trotter, S, Nicolson, M, Remmen, H, Kerr, K, Chetty, M, Gomersall, L, Fennell, DA, Nakas, A, Rathinam, S, Anand, G, Khan, S, Russell, P, Ezhil, V, Ismail, B, Irvin-sellers, M, Prakash, V, Lester, JF, Kornaszewska, M, Attanoos, R, Adams, H, Davies, H, Oukrif, D, Akarca, AU, Hartley, JA, Lowe, HL, Lock, S, Iles, N, Bell, H, Ngai, Y, Elgar, G, Szallasi, Z, Schwarz, RF, Herrero, J, Stewart, A, Quezada, SA, Van Loo, P, Dive, C, Lin, CJ, Rabinowitz, M, Aerts, HJWL, Hackshaw, A, Shaw, JA, Zimmermann, BG, Swanton, C, Bosshard-Carter, L, Goh, G, Gorman, P, Murugaesu, N, Hynds, RE, Wilson, G, Horswell, S, Al Bakir, M, Mitter, R, Escudero, M, Xu, H, Goldman, J, Stone, RK, Denner, T, Biggs, J, Costa, M, Begum, S, Phillimore, B, Nye, E, Graca, S, Joshi, K, Furness, A, Aissa, AB, Wong, YNS, Georgiou, A, Quezada, S, Simeon, C, Hector, G, Smith, A, Aranda, M, Novelli, M, Forster, M, Papadatos-Pastos, D, Carnell, D, Mendes, R, George, J, Navani, N, Taylor, M, Choudhary, J, Califano, R, Taylor, P, Krysiak, P, Rammohan, K, Fontaine, E, Booton, R, Evison, M, Moss, S, Idries, F, Bishop, P, Chaturved, A, Marie Quinn, A, Doran, H, leek, A, Harrison, P, Moore, K, Waddington, R, Novasio, J, Rogan, J, Smith, E, Tugwood, J, Brady, G, Rothwell, DG, Chemi, F, Pierce, J, Gulati, S, Bellamy, M, Bancroft, H, Kerr, A, Kadiri, S, Webb, J, Djearaman, M, Fennell, D, Le Quesne, J, Moore, D, Thomas, A, Walter, H, Monteiro, W, Marshall, H, Nelson, L, Bennett, J, Primrose, L, Amadi, A, Palmer, S, Miller, J, Buchan, K, Lester, J, Edwards, A, Morgan, F, Verjee, A, MacKenzie, M, Wilcox, M, Smith, S, Gower, N, Ottensmeier, C, Chee, S, Johnson, B, Alzetani, A, Shaw, E, Lim, E, De Sousa, P, Tavares Barbosa, M, Bowman, A, Jordan, S, Rice, A, Raubenheimer, H, Proli, C, Elena Cufari, M, Ronquillo, JC, Kwayie, A, Bhayani, H, Hamilton, M, Bakar, Y, Mensah, N, Ambrose, L, Devaraj, A, Buderi, S, Finch, J, Azcarate, L, Chavan, H, Green, S, Mashinga, H, Nicholson, AG, Lau, K, Sheaff, M, Schmid, P, Conibear, J, Light, T, Horey, T, Danson, S, Bury, J, Edwards, J, Hill, J, Matthews, S, Kitsanta, Y, Suvarna, K, Fisher, P, Keerio, AD, Shackcloth, M, Gosney, J, Postmus, P, Feeney, S, Asante-Siaw, J, Constatin, T, Zimmermann, B, Dentro, S, Dessimoz, C, Shiu, K-K, Bridgewater, J, Hochauser, D, Beck, S, Parker, P, Walczak, H, Enver, T, Proctor, I, Sinclair, R, Lok, C-W, Mitchison, M, Trevisan, G, Lynch, M, Brandner, S, Gishen, F, Tookman, A, Stone, P, Sterling, C, Larkin, J, Attard, G, Eeles, R, Foster, C, Bova, S, Sottoriva, A, Chowdhury, S, Ashish, C, Spicer, J, Stares, M, Lynch, J, Caldas, C, Brenton, J, Fitzgerald, R, Jimenez-Linan, M, Provenzano, E, Cluroe, A, Stewart, G, Watts, C, Gilbertson, R, McDermott, U, Tavare, S, Maughan, T, Tomlinson, I, Campbell, P, McNeish, I, Biankin, A, Chambers, A, Fraser, S, Oien, K, Krebs, M, Marais, R, Carter, L, Nonaka, D, Dhomen, N, Shaw, J, Baijal, S, Tanchel, B, Collard, M, Cockcroft, P, Taylor, J, Colloby, P, Olisemeke, B, Wilson, R, Harrison, D, Loda, M, Flanagan, A, McKenzie, M, Lederman, J, Sharp, A, and Farrelly, L
- Subjects
0301 basic medicine ,Oncology ,Lung Neoplasms ,IMPACT ,Biopsy ,DNA Mutational Analysis ,Drug resistance ,Metastasis ,0302 clinical medicine ,Limit of Detection ,Carcinoma, Non-Small-Cell Lung ,Medicine ,Neoplasm Metastasis ,Early Detection of Cancer ,Multidisciplinary ,medicine.diagnostic_test ,Phylogenetic tree ,DNA, Neoplasm ,STATISTICS ,3. Good health ,Tumor Burden ,Multidisciplinary Sciences ,Cell Tracking ,PEACE consortium ,030220 oncology & carcinogenesis ,Disease Progression ,Science & Technology - Other Topics ,medicine.medical_specialty ,CARCINOMA ,Tumour heterogeneity ,General Science & Technology ,Early detection ,Evolution, Molecular ,03 medical and health sciences ,Internal medicine ,MD Multidisciplinary ,Carcinoma ,Humans ,Cell Lineage ,Lung cancer ,Postoperative Care ,Science & Technology ,MUTATIONS ,TRACERx consortium ,business.industry ,CIRCULATING TUMOR DNA ,Reproducibility of Results ,medicine.disease ,R1 ,NEGATIVE BREAST-CANCER ,Clone Cells ,030104 developmental biology ,Drug Resistance, Neoplasm ,UPTAKE RATIO ,Immunology ,FDG PET ,Neoplasm Recurrence, Local ,business ,Multiplex Polymerase Chain Reaction - Abstract
The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence. The ability to track the evolutionary dynamics of early-stage lung cancer non-invasively in circulating tumour DNA (ctDNA) has not yet been demonstrated. Here we use a tumour-specific phylogenetic approach to profile the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) study participants, including one patient who was also recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release and analyse the tumour-volume detection limit. Through blinded profiling of postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are very likely to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
- Published
- 2017
18. Accounting for Tumour Movement in the Upper Abdomen using Fiducial-free Stereotactic Radiotherapy in Expiration Breath Hold: a Case Report
- Author
-
Phillips, I., primary, Earley, J., additional, Beddows, J., additional, Hussein, M., additional, Woodward, S., additional, Kelly, M., additional, Lamont, K., additional, McLachlan, C., additional, South, C., additional, West, C., additional, Adams, E., additional, Ezhil, V., additional, and Chandy, E., additional
- Published
- 2018
- Full Text
- View/download PDF
19. PO-0970: Robustness of Texture as a Biomarker in Radiomics Applications
- Author
-
Wang, H.Y.C., primary, Donovan, E., additional, Nisbet, A., additional, Alobaidli, S., additional, Phillips, I., additional, Ezhil, V., additional, Webster, P., additional, Ferreira, M., additional, and Evans, P., additional
- Published
- 2018
- Full Text
- View/download PDF
20. OC-0537: Prophylactic irradiation of tracts (PIT) in patients with pleural mesothelioma: a phase III trial
- Author
-
Bayman, N., primary, Appel, W., additional, Ashcroft, L., additional, Baldwin, D.R., additional, Bates, A., additional, Chappell, B., additional, Darlison, L., additional, Edwards, J., additional, Ezhil, V., additional, Gilligan, D., additional, Hatton, M., additional, Mansy, T., additional, Peake, M., additional, Pemberton, L., additional, Rintoul, R., additional, Ryder, W., additional, Taylor, P., additional, and Faivre-Finn, C., additional
- Published
- 2018
- Full Text
- View/download PDF
21. Prophylactic irradiation of tracts (PIT) in patients with pleural mesothelioma: results of a multicentre phase III trial
- Author
-
Bayman, N., primary, Appel, W., additional, Ashcroft, L., additional, Baldwin, D.R., additional, Bates, A.T., additional, Darlison, L., additional, Edwards, J.G., additional, Ezhil, V., additional, Gilligan, D., additional, Hatton, M., additional, Mansy, T., additional, Peake, M.D., additional, Pemberton, L., additional, Rintoul, R.C., additional, Ryder, W.D.J., additional, Taylor, P., additional, and Faivre-Finn, C., additional
- Published
- 2018
- Full Text
- View/download PDF
22. Assessing the use of SABR in stage 1 non-small cell lung cancer in England: the use of the National Radiotherapy Data Set
- Author
-
Phillips, I., primary, Ezhil, V., additional, Brock, R., additional, Henson, K., additional, and Lawton, S., additional
- Published
- 2018
- Full Text
- View/download PDF
23. OA 02.03 Prophylactic Irradiation of Tracts (PIT) in Patients with Pleural Mesothelioma: Results of a Multicenter Phase III Trial
- Author
-
Bayman, N., primary, Appel, W., additional, Ashcroft, L., additional, Baldwin, D., additional, Bates, A., additional, Darlison, L., additional, Edwards, J., additional, Ezhil, V., additional, Gilligan, D., additional, Hatton, M., additional, Mansy, T., additional, Peake, M., additional, Pemberton, L., additional, Rintoul, R., additional, Ryder, D., additional, Taylor, P., additional, and Faivre-Finn, C., additional
- Published
- 2017
- Full Text
- View/download PDF
24. Stereotactic radiotherapy for primary lung cancer
- Author
-
Phillips, I., primary, Flint, R., additional, Hin, B., additional, and Ezhil, V., additional
- Published
- 2017
- Full Text
- View/download PDF
25. EP-1562: A Dose Painting Study Based on CT Intratumoural Heterogeneity vs. FDG PET Uptake in NSCLC
- Author
-
Alobaidli, S., primary, South, C., additional, McQuaid, S., additional, Scuffham, J., additional, Phillips, I., additional, Prakash, V., additional, Ezhil, V., additional, Nisbet, A., additional, and Evans, P., additional
- Published
- 2017
- Full Text
- View/download PDF
26. Autocatalytic duplex Ni-P/Ni-W-P coatings on AZ31B magnesium alloy
- Author
-
Selvi, Ezhil V, Chatterji, Purba, Subramanian, S, and Balaraju, JN
- Subjects
Materials Engineering (formerly Metallurgy) - Abstract
Autocatalytic duplex Ni-P/Ni-W-P coatings were deposited on AZ31B magnesium alloy using stabilizer free nickel carbonate bath. Some of the coated specimens were passivated in chromate solution with and without heat treatment. Plain Ni-P coatings were also prepared for comparison. Coatings were characterized for their surface morphology, composition and corrosion resistance. Energy dispersive analysis of X-ray (EDX) showed that the phosphorous content in the Ni-P coating is 6 wt.% and for Ni-W-P it reduced to 3 wt.% due to the codeposition of tungsten in the Ni-P coating. Marginal increase in P and W contents was observed on passivated coupons along with Cr (0.18 wt.%) and O (2.8 wt.%) contents. Field emission scanning electron microscopy (FESEM) examination of these coating surfaces exhibited the nodular morphology. Chromate passivated surfaces showed the presence of uniformly distributed bright Ni particles along with nodules. Potenfiodynamic polarization and electrochemical impedance spectroscopy (EIS) studies were carried out in deaerated 0.15 M NaCI solution to find out the corrosion resistance of the coatings. Among the coatings developed, duplex-heat treated-passivated (duplex-HIP) coatings showed lower corrosion current density (i(corr)) and higher polarization resistance (R-p) indicating the improved corrosion resistance. The charge transfer resistance (R-ct) value obtained for the duplex-HIP was about 170 times higher compared to that for Ni P coating. (c) 2013 Elsevier B.V. All rights reserved.
- Published
- 2014
27. Audit of treatment of older patients with lung cancer
- Author
-
Ezhil, V., primary, Phillips, I.D., additional, Gunn, L., additional, and Nimako, K., additional
- Published
- 2016
- Full Text
- View/download PDF
28. Early mortality following radiotherapy – meeting standards and improving patient selection.
- Author
-
Lerner, A., primary, Phillips, I., additional, and Ezhil, V., additional
- Published
- 2015
- Full Text
- View/download PDF
29. Modelling and Design of Photovoltaic Fed Re-lift Luo Converter for Air Conditioner
- Author
-
U. Shajith Ali and Ezhil Venthan
- Subjects
air conditioner ,inverter ,perturb and observe mppt ,photovoltaic ,re-lift luo converter ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Technology (General) ,T1-995 - Abstract
The design of high gain converter with photovoltaic (PV) module is carried out in this paper for air conditioning application. The solar based power system gaining large importance due to the renewable nature and increased life time. To understand power and voltage characteristic of PV module, the five parameter single diode model is evolved and analyzed. Due to the varying power characteristic of PV panel to the temperature and irradiance change, perturb and observe maximum power point tracking algorithm is imposed to harvest the maximal potential PV power. Air conditioner require high currents so solar modules are connected in parallel instead of series configuration. Since the output voltage of PV module is low, it requires a DC to DC power electronic converter with large voltage gain to boost the output voltage. Various converters such as conventional boost, buck/boost and Luo converters to provide high voltage gain are analyzed in this work and Luo converter is found to give small ripple in current and voltage as compared to the other two converters for the same voltage gain. Further, in Luo converter, voltage gain can be improved by lifting technique in which self-lift and re-lift techniques are employed. The Re-lift Luo converter has high voltage gains twice that of self-lift Luo and reduced ripple for solar power application. For air conditioning application AC output is obtained using a full bridge single phase voltage source inverter.
- Published
- 2019
30. 160 The impact of age and performance status on outcome of brain metastases in non-small cell lung cancer (NSCLC)
- Author
-
Larbi, E., primary, Middleton, G., additional, Partridge-James, T., additional, Quirin, S., additional, Hardacre, V., additional, Broadbanks, C., additional, Dennis, L., additional, Russell, S., additional, Davies, C., additional, Illsley, M., additional, and Ezhil, V., additional
- Published
- 2012
- Full Text
- View/download PDF
31. 99 Comparison of 4DCT derived PTV vs. free-breathing derived PTV in patients receiving radical radiotherapy for NSCLC - volumetric and dosimetric analysis
- Author
-
Franklin, A., primary, Jones, M., additional, Barnard, A., additional, Illsley, M., additional, and Ezhil, V., additional
- Published
- 2011
- Full Text
- View/download PDF
32. Dosimetric consequences of contrast-enhanced CT planning for thoracic radiotherapy
- Author
-
Lalondrelle, S., primary, Jones, M., additional, Barnard, A., additional, Illsley, M., additional, and Ezhil, V., additional
- Published
- 2010
- Full Text
- View/download PDF
33. Early experience with mitoxantrone in aggressive relapsing-remitting multiple sclerosis. (ABN Abstracts)
- Author
-
Ezhil, V. and Boggild, M.
- Subjects
Multiple sclerosis -- Drug therapy ,Mitoxantrone hydrochloride -- Health aspects ,Health ,Psychology and mental health ,Drug therapy ,Health aspects - Abstract
Background: Data from three randomised controlled trials supports the use of mitoxantrone, a cytotoxic agent, in active relapsing and secondary progressive multiple sclerosis (MS). The drug has recently been licenced [...]
- Published
- 2002
34. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- Author
-
Abbosh, C, Birkbak, NJ, Wilson, GA, Jamal-Hanjani, M, Constantin, T, Salari, R, Le Quesne, J, Moore, DA, Veeriah, S, Rosenthal, R, Marafioti, T, Kirkizlar, E, Watkins, TBK, McGranahan, N, Ward, S, Martinson, L, Riley, J, Fraioli, F, Al Bakir, M, Grönroos, E, Zambrana, F, Endozo, R, Bi, WL, Fennessy, FM, Sponer, N, Johnson, D, Laycock, J, Shafi, S, Czyzewska-Khan, J, Rowan, A, Chambers, T, Matthews, N, Turajlic, S, Hiley, C, Lee, SM, Forster, MD, Ahmad, T, Falzon, M, Borg, E, Lawrence, D, Hayward, M, Kolvekar, S, Panagiotopoulos, N, Janes, SM, Thakrar, R, Ahmed, A, Blackhall, F, Summers, Y, Hafez, D, Naik, A, Ganguly, A, Kareht, S, Shah, R, Joseph, L, Marie Quinn, A, Crosbie, PA, Naidu, B, Middleton, G, Langman, G, Trotter, S, Nicolson, M, Remmen, H, Kerr, K, Chetty, M, Gomersall, L, Fennell, DA, Nakas, A, Rathinam, S, Anand, G, Khan, S, Russell, P, Ezhil, V, Ismail, B, Irvin-Sellers, M, Prakash, V, Lester, JF, Kornaszewska, M, Attanoos, R, Adams, H, Davies, H, Oukrif, D, Akarca, AU, Hartley, JA, Lowe, HL, Lock, S, Iles, N, Bell, H, Ngai, Y, Elgar, G, Szallasi, Z, Schwarz, RF, Herrero, J, Stewart, A, Quezada, SA, Peggs, KS, Van Loo, P, Dive, C, Lin, CJ, Rabinowitz, M, Aerts, HJWL, Hackshaw, A, Shaw, JA, Zimmermann, BG, TRACERx Consortium, PEACE Consortium, and Swanton, C
- Subjects
Postoperative Care ,Lung Neoplasms ,Biopsy ,DNA Mutational Analysis ,Reproducibility of Results ,DNA, Neoplasm ,16. Peace & justice ,3. Good health ,Clone Cells ,Tumor Burden ,Evolution, Molecular ,Cell Tracking ,Drug Resistance, Neoplasm ,Limit of Detection ,Carcinoma, Non-Small-Cell Lung ,Disease Progression ,Humans ,Cell Lineage ,Neoplasm Metastasis ,Neoplasm Recurrence, Local ,Multiplex Polymerase Chain Reaction ,Early Detection of Cancer - Abstract
The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence. The ability to track the evolutionary dynamics of early-stage lung cancer non-invasively in circulating tumour DNA (ctDNA) has not yet been demonstrated. Here we use a tumour-specific phylogenetic approach to profile the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) study participants, including one patient who was also recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release and analyse the tumour-volume detection limit. Through blinded profiling of postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are very likely to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
35. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
- Author
-
Nicholas McGranahan, Rachel Rosenthal, Crispin T. Hiley, Andrew J. Rowan, Thomas B.K. Watkins, Gareth A. Wilson, Nicolai J. Birkbak, Selvaraju Veeriah, Peter Van Loo, Javier Herrero, Charles Swanton, Mariam Jamal-Hanjani, Seema Shafi, Justyna Czyzewska-Khan, Diana Johnson, Joanne Laycock, Leticia Bosshard-Carter, Pat Gorman, Robert E. Hynds, Gareth Wilson, Stuart Horswell, Richard Mitter, Mickael Escudero, Aengus Stewart, Andrew Rowan, Hang Xu, Samra Turajlic, Crispin Hiley, Christopher Abbosh, Jacki Goldman, Richard Kevin Stone, Tamara Denner, Nik Matthews, Greg Elgar, Sophia Ward, Marta Costa, Sharmin Begum, Ben Phillimore, Tim Chambers, Emma Nye, Sofia Graca, Maise Al Bakir, Kroopa Joshi, Andrew Furness, Assma Ben Aissa, Yien Ning Sophia Wong, Andy Georgiou, Sergio Quezada, John A. Hartley, Helen L. Lowe, David Lawrence, Martin Hayward, Nikolaos Panagiotopoulos, Shyam Kolvekar, Mary Falzon, Elaine Borg, Teresa Marafioti, Celia Simeon, Gemma Hector, Amy Smith, Marie Aranda, Marco Novelli, Dahmane Oukrif, Sam M. Janes, Ricky Thakrar, Martin Forster, Tanya Ahmad, Siow Ming Lee, Dionysis Papadatos-Pastos, Dawn Carnell, Ruheena Mendes, Jeremy George, Neal Navani, Asia Ahmed, Magali Taylor, Junaid Choudhary, Yvonne Summers, Raffaele Califano, Paul Taylor, Rajesh Shah, Piotr Krysiak, Kendadai Rammohan, Eustace Fontaine, Richard Booton, Matthew Evison, Phil Crosbie, Stuart Moss, Faiza Idries, Leena Joseph, Paul Bishop, Anshuman Chaturved, Anne Marie Quinn, Helen Doran, Angela Leek, Phil Harrison, Katrina Moore, Rachael Waddington, Juliette Novasio, Fiona Blackhall, Jane Rogan, Elaine Smith, Caroline Dive, Jonathan Tugwood, Ged Brady, Dominic G. Rothwell, Francesca Chemi, Jackie Pierce, Sakshi Gulati, Babu Naidu, Gerald Langman, Simon Trotter, Mary Bellamy, Hollie Bancroft, Amy Kerr, Salma Kadiri, Joanne Webb, Gary Middleton, Madava Djearaman, Dean Fennell, Jacqui A. Shaw, John Le Quesne, David Moore, Apostolos Nakas, Sridhar Rathinam, William Monteiro, Hilary Marshall, Louise Nelson, Jonathan Bennett, Joan Riley, Lindsay Primrose, Luke Martinson, Girija Anand, Sajid Khan, Anita Amadi, Marianne Nicolson, Keith Kerr, Shirley Palmer, Hardy Remmen, Joy Miller, Keith Buchan, Mahendran Chetty, Lesley Gomersall, Jason Lester, Alison Edwards, Fiona Morgan, Haydn Adams, Helen Davies, Malgorzata Kornaszewska, Richard Attanoos, Sara Lock, Azmina Verjee, Mairead MacKenzie, Maggie Wilcox, Harriet Bell, Allan Hackshaw, Yenting Ngai, Sean Smith, Nicole Gower, Christian Ottensmeier, Serena Chee, Benjamin Johnson, Aiman Alzetani, Emily Shaw, Eric Lim, Paulo De Sousa, Monica Tavares Barbosa, Alex Bowman, Simon Jordan, Alexandra Rice, Hilgardt Raubenheimer, Chiara Proli, Maria Elena Cufari, John Carlo Ronquillo, Angela Kwayie, Harshil Bhayani, Morag Hamilton, Yusura Bakar, Natalie Mensah, Lyn Ambrose, Anand Devaraj, Silviu Buderi, Jonathan Finch, Leire Azcarate, Hema Chavan, Sophie Green, Hillaria Mashinga, Andrew G. Nicholson, Kelvin Lau, Michael Sheaff, Peter Schmid, John Conibear, Veni Ezhil, Babikir Ismail, Melanie Irvin-sellers, Vineet Prakash, Peter Russell, Teresa Light, Tracey Horey, Sarah Danson, Jonathan Bury, John Edwards, Jennifer Hill, Sue Matthews, Yota Kitsanta, Kim Suvarna, Patricia Fisher, Allah Dino Keerio, Michael Shackcloth, John Gosney, Pieter Postmus, Sarah Feeney, Julius Asante-Siaw, Hugo J.W.L. Aerts, Stefan Dentro, Christophe Dessimoz, TRACERx Consortium, Swanton, C., Jamal-Hanjani, M., Veeriah, S., Shafi, S., Czyzewska-Khan, J., Johnson, D., Laycock, J., Bosshard-Carter, L., Rosenthal, R., Gorman, P., Hynds, R.E., Wilson, G., Birkbak, N.J., Watkins, TBK, McGranahan, N., Horswell, S., Mitter, R., Escudero, M., Stewart, A., Van Loo, P., Rowan, A., Xu, H., Turajlic, S., Hiley, C., Abbosh, C., Goldman, J., Stone, R.K., Denner, T., Matthews, N., Elgar, G., Ward, S., Costa, M., Begum, S., Phillimore, B., Chambers, T., Nye, E., Graca, S., Al Bakir, M., Joshi, K., Furness, A., Ben Aissa, A., Wong, YNS, Georgiou, A., Quezada, S., Hartley, J.A., Lowe, H.L., Herrero, J., Lawrence, D., Hayward, M., Panagiotopoulos, N., Kolvekar, S., Falzon, M., Borg, E., Marafioti, T., Simeon, C., Hector, G., Smith, A., Aranda, M., Novelli, M., Oukrif, D., Janes, S.M., Thakrar, R., Forster, M., Ahmad, T., Lee, S.M., Papadatos-Pastos, D., Carnell, D., Mendes, R., George, J., Navani, N., Ahmed, A., Taylor, M., Choudhary, J., Summers, Y., Califano, R., Taylor, P., Shah, R., Krysiak, P., Rammohan, K., Fontaine, E., Booton, R., Evison, M., Crosbie, P., Moss, S., Idries, F., Joseph, L., Bishop, P., Chaturved, A., Quinn, A.M., Doran, H., Leek, A., Harrison, P., Moore, K., Waddington, R., Novasio, J., Blackhall, F., Rogan, J., Smith, E., Dive, C., Tugwood, J., Brady, G., Rothwell, D.G., Chemi, F., Pierce, J., Gulati, S., Naidu, B., Langman, G., Trotter, S., Bellamy, M., Bancroft, H., Kerr, A., Kadiri, S., Webb, J., Middleton, G., Djearaman, M., Fennell, D., Shaw, J.A., Le Quesne, J., Moore, D., Nakas, A., Rathinam, S., Monteiro, W., Marshall, H., Nelson, L., Bennett, J., Riley, J., Primrose, L., Martinson, L., Anand, G., Khan, S., Amadi, A., Nicolson, M., Kerr, K., Palmer, S., Remmen, H., Miller, J., Buchan, K., Chetty, M., Gomersall, L., Lester, J., Edwards, A., Morgan, F., Adams, H., Davies, H., Kornaszewska, M., Attanoos, R., Lock, S., Verjee, A., MacKenzie, M., Wilcox, M., Bell, H., Hackshaw, A., Ngai, Y., Smith, S., Gower, N., Ottensmeier, C., Chee, S., Johnson, B., Alzetani, A., Shaw, E., Lim, E., De Sousa, P., Barbosa, M.T., Bowman, A., Jordan, S., Rice, A., Raubenheimer, H., Proli, C., Cufari, M.E., Ronquillo, J.C., Kwayie, A., Bhayani, H., Hamilton, M., Bakar, Y., Mensah, N., Ambrose, L., Devaraj, A., Buderi, S., Finch, J., Azcarate, L., Chavan, H., Green, S., Mashinga, H., Nicholson, A.G., Lau, K., Sheaff, M., Schmid, P., Conibear, J., Ezhil, V., Ismail, B., Irvin-Sellers, M., Prakash, V., Russell, P., Light, T., Horey, T., Danson, S., Bury, J., Edwards, J., Hill, J., Matthews, S., Kitsanta, Y., Suvarna, K., Fisher, P., Keerio, A.D., Shackcloth, M., Gosney, J., Postmus, P., Feeney, S., Asante-Siaw, J., Aerts, HJWL, Dentro, S., and Dessimoz, C.
- Subjects
Male ,immune-editing ,0301 basic medicine ,DOWN-REGULATION ,immune-escape ,Lung Neoplasms ,Loss of Heterozygosity ,Cohort Studies ,Loss of heterozygosity ,HLA Antigens ,Carcinoma, Non-Small-Cell Lung ,Chromosome instability ,MUTATIONAL PROCESSES ,11 Medical and Health Sciences ,Aged, 80 and over ,Antigen Presentation ,cancer evolution ,Manchester Cancer Research Centre ,bioinformatics ,Middle Aged ,3. Good health ,Female ,loss of heterozygosity ,SENSITIVITY ,Life Sciences & Biomedicine ,Adult ,Biochemistry & Molecular Biology ,chromosomal instability ,Antigen presentation ,Locus (genetics) ,NEOANTIGENS ,Human leukocyte antigen ,Biology ,Polymorphism, Single Nucleotide ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Immune system ,copy number ,medicine ,Humans ,Lung cancer ,Aged ,Science & Technology ,ResearchInstitutes_Networks_Beacons/mcrc ,CTLA-4 BLOCKADE ,Cell Biology ,06 Biological Sciences ,medicine.disease ,PD-1 BLOCKADE ,neoantigen ,lung cancer ,030104 developmental biology ,Carcinoma, Non-Small-Cell Lung/genetics ,Carcinoma, Non-Small-Cell Lung/immunology ,Carcinoma, Non-Small-Cell Lung/pathology ,Carcinoma, Non-Small-Cell Lung/therapy ,HLA Antigens/genetics ,HLA Antigens/immunology ,Lung Neoplasms/genetics ,Lung Neoplasms/immunology ,Lung Neoplasms/pathology ,Lung Neoplasms/therapy ,Mutation ,Tumor Escape ,heterogeneity ,TRACERx Consortium ,DISCOVERY ,CELLS ,Immunology ,RESISTANCE ,Developmental Biology - Abstract
Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune evasion. However, the polymorphic nature of the locus has precluded accurate HLA copy-number analysis. Here, we present loss of heterozygosity in human leukocyte antigen (LOHHLA), a computational tool to determine HLA allele-specific copy number from sequencing data. Using LOHHLA, we find that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated with a high subclonal neoantigen burden, APOBEC-mediated mutagenesis, upregulation of cytolytic activity, and PD-L1 positivity. The focal nature of HLA LOH alterations, their subclonal frequencies, enrichment in metastatic sites, and occurrence as parallel events suggests that HLA LOH is an immune escape mechanism that is subject to strong microenvironmental selection pressures later in tumor evolution. Characterizing HLA LOH with LOHHLA refines neoantigen prediction and may have implications for our understanding of resistance mechanisms and immunotherapeutic approaches targeting neoantigens. VIDEO ABSTRACT.
- Published
- 2017
36. Nutritional status and symptom burden in advanced non-small cell lung cancer: results of the dietetic assessment and intervention in lung cancer (DAIL) trial.
- Author
-
Phillips I, Allan L, Hug A, Westran N, Heinemann C, Hewish M, Mehta A, Saxby H, and Ezhil V
- Subjects
- Humans, Nutritional Status, Pilot Projects, Nutrition Assessment, Weight Loss, Carcinoma, Non-Small-Cell Lung complications, Carcinoma, Non-Small-Cell Lung diagnosis, Dietetics, Lung Neoplasms complications, Lung Neoplasms diagnosis, Malnutrition diagnosis, Malnutrition prevention & control
- Abstract
Introduction: European Society for Clinical Nutrition and Metabolism guidelines recommend that patients with cancer should be screened for malnutrition at diagnosis. The dietetic assessment and intervention in lung cancer study investigated the nutritional status of patients with non-small cell lung cancer (NSCLC) and the need for dietetic intervention., Methods: In this observational cohort pilot study, patients with stage 3b and 4 NSCLC were assessed prior to starting first line systemic anticancer therapy (SACT) with a range of measurements and questionnaires. We report the outcomes related to the Patient Generated Subjective Global Assessment tool (PG-SGA), RESULTS: 96 patients were consented between April 2017 and August 2019. The PG-SGA identified that 78% of patients required specialist nutritional advice; with 52% patients having a critical need for dietetic input and symptom management. Results were dominated by symptom scores. As a screening test, one or more symptoms or recent weight loss history had a sensitivity of 88% (95% CI 78.44% to 94.36%) and specificity of 95.24% (95% CI 76.18% to 99.88%) for need for dietetic intervention., Conclusion: A large proportion of patients with NSCLC have a high symptom burden and are at risk of malnutrition prior to starting SACT and would benefit from dietetic review. It is imperative that oncologists and healthcare professionals discuss weight loss history and symptoms with lung cancer patients to correct nutritional deficiencies and resolve symptoms prior to starting treatment., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
37. Common Cholinergic, Noradrenergic, and Serotonergic Drugs Do Not Block VNS-Mediated Plasticity.
- Author
-
Morrison RA, Abe ST, Danaphongse T, Ezhil V, Somaney A, Adcock KS, Rennaker RL, Kilgard MP, and Hays SA
- Abstract
Vagus nerve stimulation (VNS) delivered during motor rehabilitation enhances recovery from a wide array of neurological injuries and was recently approved by the U.S. FDA for chronic stroke. The benefits of VNS result from precisely timed engagement of neuromodulatory networks during rehabilitative training, which promotes synaptic plasticity in networks activated by rehabilitation. Previous studies demonstrate that lesions that deplete these neuromodulatory networks block VNS-mediated plasticity and accompanying enhancement of recovery. There is a great deal of interest in determining whether commonly prescribed pharmacological interventions that influence these neuromodulatory networks would similarly impair VNS effects. Here, we sought to directly test the effects of three common pharmaceuticals at clinically relevant doses that target neuromodulatory pathways on VNS-mediated plasticity in rats. To do so, rats were trained on a behavioral task in which jaw movement during chewing was paired with VNS and received daily injections of either oxybutynin, a cholinergic antagonist, prazosin, an adrenergic antagonist, duloxetine, a serotonin-norepinephrine reuptake inhibitor, or saline. After the final behavioral session, intracortical microstimulation (ICMS) was used to evaluate reorganization of motor cortex representations, with area of cortex eliciting jaw movement as the primary outcome. In animals that received control saline injections, VNS paired with training significantly increased the movement representation of the jaw compared to naïve animals, consistent with previous studies. Similarly, none of the drugs tested blocked this VNS-dependent reorganization of motor cortex. The present results provide direct evidence that these common pharmaceuticals, when used at clinically relevant doses, are unlikely to adversely impact the efficacy of VNS therapy., Competing Interests: MK has a financial interest in MicroTransponder, Inc., which is developing VNS for stroke. RR has a financial interest in Xnerve Medical, Inc., which is developing several VNS based therapies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Morrison, Abe, Danaphongse, Ezhil, Somaney, Adcock, Rennaker, Kilgard and Hays.)
- Published
- 2022
- Full Text
- View/download PDF
38. High intensity VNS disrupts VNS-mediated plasticity in motor cortex.
- Author
-
Morrison RA, Danaphongse TT, Abe ST, Stevens ME, Ezhil V, Seyedahmadi A, Adcock KS, Rennaker RL, Kilgard MP, and Hays SA
- Subjects
- Animals, Female, Mastication physiology, Rats, Sprague-Dawley, Recovery of Function physiology, Rats, Motor Cortex physiology, Movement physiology, Neuronal Plasticity physiology, Vagus Nerve Stimulation methods
- Abstract
Vagus nerve stimulation (VNS) paired with motor rehabilitation enhances recovery of function after neurological injury in rats and humans. This effect is ascribed to VNS-dependent facilitation of plasticity in motor networks. Previous studies document an inverted-U relationship between VNS intensity and cortical plasticity, such that moderate intensities increase plasticity, while low or high intensity VNS does not. We tested the interaction of moderate and high intensity VNS trains to probe the mechanisms that may underlie VNS-dependent plasticity. Rats performed a behavioral task where VNS was paired with jaw movement during chewing. For five days, subjects received 100 pairings of moderate intensity VNS (Standard VNS), 100 pairings alternating between moderate and high intensity VNS (Interleaved VNS), or 50 pairings of moderate intensity VNS (Short VNS) approximately every 8 s. After the final behavioral session, intracortical microstimulation (ICMS) was used to evaluate movement representations in motor cortex. 100 pairings of moderate intensity VNS enhanced motor cortex plasticity. Replacing half of moderate intensity stimulation with high intensity VNS blocked this enhancement of plasticity. Removing high intensity stimulation, leaving only 50 pairings of moderate intensity VNS, reinstated plasticity. These results demonstrate that there is a period for at least 8 s after high intensity stimulation in which moderate intensity VNS is not able to engage mechanisms required for synaptic reorganization. More importantly, this study demonstrates that changes in stimulation parameters are a critical determinant of the magnitude of plasticity and likely the efficacy of VNS-enhanced recovery., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
39. Dietetic assessment and intervention in lung cancer.
- Author
-
Phillips I, Hug A, Allan L, and Ezhil V
- Subjects
- Biomarkers, Body Composition physiology, Cachexia therapy, Dietary Supplements, Exercise, Humans, Malnutrition diagnosis, Malnutrition etiology, Muscle, Skeletal metabolism, Palliative Care, Practice Guidelines as Topic, Quality of Life, Sarcopenia diagnosis, Sarcopenia etiology, Weight Loss, Cachexia diagnosis, Cachexia etiology, Lung Neoplasms complications, Nutrition Assessment
- Abstract
Purpose of Review: Systemic therapy for lung cancer is increasing in intensity and duration. European nutrition guidelines suggest screening for weight loss and malnutrition, however acknowledges there is a lack of evidence. We discuss current data round this issue and identify opportunities for further research., Recent Findings: International guidelines now exist to aid the definition of weight loss in cancer, including cachexia, sarcopenia and malnutrition. These allow consistent definition of overlapping, but distinct clinical syndromes. Nutritional status can be assessed in a range of ways including questionnaires, functional assessments, blood markers, physical activity, weight and BMI. Weight loss is commonly associated with a proinflammatory state. Future treatment is likely to be a combination of dietetic support and pharmacological treatment of cachexia., Summary: There is a paucity of data on dietetic intervention. It is potentially quick, inexpensive and patient specific, using a holistic approach to aid patients who are malnourished or at risk of malnutrition. Lung cancer-related weight loss is common, further strategies are needed to effectively assess and intervene. Dietetic intervention has the potential to improve patients' quality of life and outcomes.
- Published
- 2019
- Full Text
- View/download PDF
40. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.
- Author
-
Bayman N, Appel W, Ashcroft L, Baldwin DR, Bates A, Darlison L, Edwards JG, Ezhil V, Gilligan D, Hatton M, Jegannathen A, Mansy T, Peake MD, Pemberton L, Rintoul RC, Snee M, Ryder WD, Taylor P, and Faivre-Finn C
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Lung Neoplasms pathology, Male, Mesothelioma pathology, Mesothelioma, Malignant, Middle Aged, Pleural Neoplasms pathology, Thoracic Neoplasms radiotherapy, Thoracic Wall pathology, Lung Neoplasms radiotherapy, Mesothelioma radiotherapy, Pleural Neoplasms radiotherapy, Thoracic Neoplasms prevention & control, Thoracic Neoplasms secondary, Thoracic Wall radiation effects
- Abstract
Purpose: Prophylactic irradiation to the chest wall after diagnostic or therapeutic procedures in patients with malignant pleural mesothelioma (MPM) has been a widespread practice across Europe, although the efficacy of this treatment is uncertain. In this study, we aimed to determine the efficacy of prophylactic radiotherapy in reducing the incidence of chest wall metastases (CWM) after a procedure in MPM., Methods: After undergoing a chest wall procedure, patients with MPM were randomly assigned to receive prophylactic radiotherapy (within 42 days of the procedure) or no radiotherapy. Open thoracotomies, needle biopsies, and indwelling pleural catheters were excluded. Prophylactic radiotherapy was delivered at a dose of 21 Gy in three fractions over three consecutive working days, using a single electron field adapted to maximize coverage of the tract from skin surface to pleura. The primary outcome was the incidence of CWM within 6 months from random assignment, assessed in the intention-to-treat population. Stratification factors included epithelioid histology and intention to give chemotherapy., Results: Between July 30, 2012, and December 12, 2015, 375 patients were recruited from 54 centers and randomly assigned to receive prophylactic radiotherapy (n = 186) or no prophylactic radiotherapy (n = 189). Participants were well matched at baseline. No significant difference was seen in the incidence of CWM at 6 months between the prophylactic radiotherapy and no radiotherapy groups (no. [%]: 6 [3.2] v 10 [5.3], respectively; odds ratio, 0.60; 95% CI, 0.17 to 1.86; P = .44). Skin toxicity was the most common radiotherapy-related adverse event in the prophylactic radiotherapy group, with 96 patients (51.6%) receiving grade 1; 19 (10.2%), grade 2; and 1 (0.5%) grade 3 radiation dermatitis (Common Terminology Criteria for Adverse Events, version 4.0)., Conclusion: There is no role for the routine use of prophylactic irradiation to chest wall procedure sites in patients with MPM.
- Published
- 2019
- Full Text
- View/download PDF
41. Textural analysis and lung function study: Predicting lung fitness for radiotherapy from a CT scan.
- Author
-
Phillips I, Ezhil V, Hussein M, South C, Nisbet A, Alobaidli S, Prakash V, Ajaz M, Wang H, and Evans P
- Abstract
Objective: This study tested the hypothesis that shows advanced image analysis can differentiate fit and unfit patients for radical radiotherapy from standard radiotherapy planning imaging, when compared to formal lung function tests, FEV1 (forced expiratory volume in 1 s) and TLCO (transfer factor of carbon monoxide)., Methods: An apical region of interest (ROI) of lung parenchyma was extracted from a standard radiotherapy planning CT scan. Software using a grey level co-occurrence matrix (GLCM) assigned an entropy score to each voxel, based on its similarity to the voxels around it., Results: Density and entropy scores were compared between a cohort of 29 fit patients (defined as FEV1 and TLCO above 50 % predicted value) and 32 unfit patients (FEV1 or TLCO below 50% predicted). Mean and median density and median entropy were significantly different between fit and unfit patients ( p = 0.005, 0.0008 and 0.0418 respectively; two-sided Mann-Whitney test)., Conclusion: Density and entropy assessment can differentiate between fit and unfit patients for radical radiotherapy, using standard CT imaging., Advances in Knowledge: This study shows that a novel assessment can generate further data from standard CT imaging. These data could be combined with existing studies to form a multiorgan patient fitness assessment from a single CT scan., (© 2019 The Authors. Published by the British Institute of Radiology.)
- Published
- 2019
- Full Text
- View/download PDF
42. Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
- Author
-
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, and Swanton C
- Abstract
This corrects the article DOI: 10.1038/nature22364.
- Published
- 2018
- Full Text
- View/download PDF
43. Clinical applications of textural analysis in non-small cell lung cancer.
- Author
-
Phillips I, Ajaz M, Ezhil V, Prakash V, Alobaidli S, McQuaid SJ, South C, Scuffham J, Nisbet A, and Evans P
- Subjects
- Humans, Positron Emission Tomography Computed Tomography methods, Tomography, X-Ray Computed methods, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Image Interpretation, Computer-Assisted methods, Lung Neoplasms diagnostic imaging
- Abstract
Lung cancer is the leading cause of cancer mortality worldwide. Treatment pathways include regular cross-sectional imaging, generating large data sets which present intriguing possibilities for exploitation beyond standard visual interpretation. This additional data mining has been termed "radiomics" and includes semantic and agnostic approaches. Textural analysis (TA) is an example of the latter, and uses a range of mathematically derived features to describe an image or region of an image. Often TA is used to describe a suspected or known tumour. TA is an attractive tool as large existing image sets can be submitted to diverse techniques for data processing, presentation, interpretation and hypothesis testing with annotated clinical outcomes. There is a growing anthology of published data using different TA techniques to differentiate between benign and malignant lung nodules, differentiate tissue subtypes of lung cancer, prognosticate and predict outcome and treatment response, as well as predict treatment side effects and potentially aid radiotherapy planning. The aim of this systematic review is to summarize the current published data and understand the potential future role of TA in managing lung cancer.
- Published
- 2018
- Full Text
- View/download PDF
44. Factors influencing the robustness of P-value measurements in CT texture prognosis studies.
- Author
-
McQuaid S, Scuffham J, Alobaidli S, Prakash V, Ezhil V, Nisbet A, South C, and Evans P
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Image Processing, Computer-Assisted, Kaplan-Meier Estimate, Male, Middle Aged, Prognosis, Retrospective Studies, Lung Neoplasms diagnostic imaging, Tomography, X-Ray Computed methods
- Abstract
Several studies have recently reported on the value of CT texture analysis in predicting survival, although the topic remains controversial, with further validation needed in order to consolidate the evidence base. The aim of this study was to investigate the effect of varying the input parameters in the Kaplan-Meier analysis, to determine whether the resulting P-value can be considered to be a robust indicator of the parameter's prognostic potential. A retrospective analysis of the CT-based normalised entropy of 51 patients with lung cancer was performed and overall survival data for these patients were collected. A normalised entropy cut-off was chosen to split the patient cohort into two groups and log-rank testing was performed to assess the survival difference of the two groups. This was repeated for varying normalised entropy cut-offs and varying follow-up periods. Our findings were also compared with previously published results to assess robustness of this parameter in a multi-centre patient cohort. The P-value was found to be highly sensitive to the choice of cut-off value, with small changes in cut-off producing substantial changes in P. The P-value was also sensitive to follow-up period, with particularly noisy results at short follow-up periods. Using matched conditions to previously published results, a P-value of 0.162 was obtained. Survival analysis results can be highly sensitive to the choice in texture cut-off value in dichotomising patients, which should be taken into account when performing such studies to avoid reporting false positive results. Short follow-up periods also produce unstable results and should therefore be avoided to ensure the results produced are reproducible. Previously published findings that indicated the prognostic value of normalised entropy were not replicated here, but further studies with larger patient numbers would be required to determine the cause of the different outcomes.
- Published
- 2017
- Full Text
- View/download PDF
45. Tracking the Evolution of Non-Small-Cell Lung Cancer.
- Author
-
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, and Swanton C
- Subjects
- Carcinoma, Non-Small-Cell Lung mortality, DNA Copy Number Variations, Disease-Free Survival, Evolution, Molecular, Exome, Female, Humans, Lung Neoplasms mortality, Male, Phylogeny, Prognosis, Prospective Studies, Risk Factors, Sequence Analysis, DNA methods, Carcinoma, Non-Small-Cell Lung genetics, Chromosomal Instability, Genetic Heterogeneity, Lung Neoplasms genetics, Mutation, Neoplasm Recurrence, Local genetics
- Abstract
Background: Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. We wanted to prospectively investigate intratumor heterogeneity in relation to clinical outcome and to determine the clonal nature of driver events and evolutionary processes in early-stage NSCLC., Methods: In this prospective cohort study, we performed multiregion whole-exome sequencing on 100 early-stage NSCLC tumors that had been resected before systemic therapy. We sequenced and analyzed 327 tumor regions to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the relationship between intratumor heterogeneity and recurrence-free survival., Results: We observed widespread intratumor heterogeneity for both somatic copy-number alterations and mutations. Driver mutations in EGFR, MET, BRAF, and TP53 were almost always clonal. However, heterogeneous driver alterations that occurred later in evolution were found in more than 75% of the tumors and were common in PIK3CA and NF1 and in genes that are involved in chromatin modification and DNA damage response and repair. Genome doubling and ongoing dynamic chromosomal instability were associated with intratumor heterogeneity and resulted in parallel evolution of driver somatic copy-number alterations, including amplifications in CDK4, FOXA1, and BCL11A. Elevated copy-number heterogeneity was associated with an increased risk of recurrence or death (hazard ratio, 4.9; P=4.4×10
-4 ), which remained significant in multivariate analysis., Conclusions: Intratumor heterogeneity mediated through chromosome instability was associated with an increased risk of recurrence or death, a finding that supports the potential value of chromosome instability as a prognostic predictor. (Funded by Cancer Research UK and others; TRACERx ClinicalTrials.gov number, NCT01888601 .).- Published
- 2017
- Full Text
- View/download PDF
46. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
- Author
-
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, and Swanton C
- Subjects
- Biopsy methods, Carcinoma, Non-Small-Cell Lung blood, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung surgery, Cell Tracking, Clone Cells metabolism, Clone Cells pathology, DNA Mutational Analysis, Disease Progression, Drug Resistance, Neoplasm genetics, Early Detection of Cancer methods, Humans, Limit of Detection, Lung Neoplasms blood, Lung Neoplasms pathology, Lung Neoplasms surgery, Multiplex Polymerase Chain Reaction, Neoplasm Metastasis genetics, Neoplasm Metastasis pathology, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local pathology, Postoperative Care methods, Reproducibility of Results, Tumor Burden, Carcinoma, Non-Small-Cell Lung genetics, Cell Lineage genetics, DNA, Neoplasm blood, DNA, Neoplasm genetics, Evolution, Molecular, Lung Neoplasms genetics, Neoplasm Metastasis diagnosis, Neoplasm Recurrence, Local diagnosis
- Abstract
The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence. The ability to track the evolutionary dynamics of early-stage lung cancer non-invasively in circulating tumour DNA (ctDNA) has not yet been demonstrated. Here we use a tumour-specific phylogenetic approach to profile the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) study participants, including one patient who was also recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release and analyse the tumour-volume detection limit. Through blinded profiling of postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are very likely to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
- Published
- 2017
- Full Text
- View/download PDF
47. Mathematical modelling of tumour volume dynamics in response to stereotactic ablative radiotherapy for non-small cell lung cancer.
- Author
-
Tariq I, Humbert-Vidan L, Chen T, South CP, Ezhil V, Kirkby NF, Jena R, and Nisbet A
- Subjects
- Carcinoma, Non-Small-Cell Lung radiotherapy, Humans, Algorithms, Carcinoma, Non-Small-Cell Lung pathology, Radiosurgery methods, Radiotherapy Planning, Computer-Assisted methods, Tumor Burden radiation effects
- Abstract
This paper reports a modelling study of tumour volume dynamics in response to stereotactic ablative radiotherapy (SABR). The main objective was to develop a model that is adequate to describe tumour volume change measured during SABR, and at the same time is not excessively complex as lacking support from clinical data. To this end, various modelling options were explored, and a rigorous statistical method, the Akaike information criterion, was used to help determine a trade-off between model accuracy and complexity. The models were calibrated to the data from 11 non-small cell lung cancer patients treated with SABR. The results showed that it is feasible to model the tumour volume dynamics during SABR, opening up the potential for using such models in a clinical environment in the future.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.